Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance).
- Citation:
- Hematol Oncol vol 31 (suppl 1) abstr 089
- Meeting Instance:
- ASH 2013
- Year:
- 2013
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3168
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- L. D. Kaplan S. H. Jung N. C. Bartlett J. Johnson J. Byrd K. Blum W. Stock A. S. Lacasce E. Hsi D. Hurd M. S. Czuczman B. D. Cheson
- Networks:
- Study
- CALGB-50403
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: